Return of research results from pharmacogenomic versus disease susceptibility studies: what’s drugs got to do with it?

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.13, Iss.8, 2012-06, pp. : 935-949

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Disclosure of individual pharmacogenomic results in research projects: when and what kind of information to return to research participants

By Korol Sandra Hurlimann Thierry Godard Béatrice de Denus Simon

Pharmacogenomics, Vol. 14, Iss. 6, 2013-04 ,pp. : 675-688

Future Medicine

Access to resources Recommend Favorite

The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what’s genetics got to do with it?

By Shelton John G Steelman Linda S Abrams Steve L Bertrand Fred E Franklin Richard A McMahon Martin McCubrey James A

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 5, 2005-10 ,pp. : 1009-1030

Informa Healthcare

Access to resources Recommend Favorite

INTRODUCTION: Return of Research Results: What About the Family?

THE JOURNAL OF LAW, MEDICINE & ETHICS, Vol. 43, Iss. 3, 2015-09 ,pp. : 437-439

John Wiley & Sons Inc

Access to resources Recommend Favorite

Research Highlights: Highlights from the latest pharmacogenomic genome-wide association studies

By Mlakar Vid Marc Janja

Pharmacogenomics, Vol. 14, Iss. 4, 2013-03 ,pp. : 357-360

Future Medicine

Access to resources Recommend Favorite

Alzheimer’’s disease and genetics of inflammation: a pharmacogenomic vision

By Vasto Sonya Candore Giuseppina Duro Giovanni Lio Domenico Grimaldi Maria Paola Caruso Calogero

Pharmacogenomics, Vol. 8, Iss. 12, 2007-12 ,pp. : 1735-1745

Future Medicine

Access to resources Recommend Favorite